WebApr 27, 2024 · Galecto concludes enrolment in Phase IIb IPF treatment trial The randomised, multicentre trial will analyse the safety and efficacy of GB0139 in 141 IPF patients. Vishnu Priyan Galecto has concluded subject enrolment in the Phase IIb GALACTIC-1 clinical trial of GB0139 to treat idiopathic pulmonary fibrosis (IPF). WebNov 13, 2024 · A multicenter, international, randomized, double-blind, placebo-controlled, event-driven phase 3 trial, the Global Approach To Lowering Adverse Cardiac Outcomes Through Improving Contractility In Heart Failure (GALACTIC-HF) trial screened more than 10,000 patients across 35 countries with the aim of determining the effects of omecamtiv …
Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 …
WebApr 26, 2024 · GALACTIC-1 trial on track to deliver top-line results in mid-2024. BOSTON, April 26, 2024(GLOBE NEWSWIRE) -- Galecto, Inc.(NASDAQ: GLTO), a clinical stage … WebJul 14, 2024 · GALACTIC-1 is a 52-week (one-year-long) trial being conducted at more than 100 sites worldwide. Its goal is to evaluate the efficacy and safety of GB0139 in IPF patients, ages 40 and older. The new trial protocol will retain the same statistical power needed to assess the primary outcome of a decline in forced vital capacity or FVC. raymond vauclair projects winnipeg
Galecto concludes enrolment in Phase IIb IPF treatment trial
WebMay 17, 2024 · The GALACTIC-HF trial showed that omecamtiv mecarbil was superior to placebo at improving cardiovascular outcomes. Description: The goal of the trial was to evaluate the selective cardiac myosin activator omecamtiv mecarbil compared with placebo among patients with heart failure with reduced ejection fraction (HFrEF). Study Design … WebMay 22, 2024 · On May 6, Galecto announced that it had recruited more than 150 patients to date for its Phase IIb GALACTIC-1 study of GB0139 (formerly TD139) for idiopathic pulmonary fibrosis (IPF). GP0139 is an inhaled galectin-3 inhibitor. WebHome > American Thoracic Society International Conference Abstracts > B34. ILD CELLULAR MECHANISMS > Galactic-1: A Randomized, Double-Blind, Multicentre, … raymond veasey obituary